CD4+ T细胞通过骨髓驻留巨噬细胞杀伤多发性骨髓瘤细胞
该研究在小鼠多发性骨髓瘤模型中,发现过继转移独特型特异性CD4+ T细胞可对已建立的骨髓多发性骨髓瘤产生治愈性应答;杀伤由摄取并呈递分泌型骨髓瘤蛋白的骨髓驻留CD11b+F4/80+MHC-II^高巨噬细胞所 orchestrate。
要点
- 过继转移独特型特异性CD4+ T细胞可对小鼠已建立的骨髓多发性骨髓瘤产生治愈性应答
- 杀伤由骨髓驻留CD11b+F4/80+MHC-II^高巨噬细胞 orchestrate,该群细胞摄取并呈递分泌型骨髓瘤蛋白
- 驻留巨噬细胞是骨髓内肿瘤杀伤的有力介导者,为多发性骨髓瘤等骨髓受累恶性肿瘤提供新策略基础
核心结论
- 骨髓驻留CD11b+F4/80+MHC-II^高巨噬细胞通过摄取并呈递分泌型骨髓瘤蛋白 orchestrate CD4+ T细胞对骨髓瘤细胞的杀伤。
- 驻留巨噬细胞是骨髓内肿瘤杀伤的有力介导者,为多发性骨髓瘤及其他累及骨髓的恶性肿瘤提供新治疗策略的基础。
研究设计与样本
- 研究使用小鼠多发性骨髓瘤模型,进行过继转移独特型特异性CD4+ T细胞,并对骨髓微环境内抗肿瘤CD4+ T细胞应答进行功能表征。
主要发现
- 过继转移独特型特异性CD4+ T细胞可对已建立的骨髓内多灶性骨髓瘤产生治愈性应答。
- 杀伤骨髓瘤细胞由骨髓驻留CD11b+F4/80+MHC-II^高巨噬细胞 orchestrate,该群细胞已摄取并呈递分泌型骨髓瘤蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD4+ T cells may induce potent antitumor immune responses through interaction with antigen-presenting cells within the tumor microenvironment. Using a murine model of multiple myeloma, we demonstrated that adoptive transfer of idiotype-specific CD4+ T cells may elicit curative responses against established multifocal myeloma in bone marrow. This finding indicates that the myeloma bone marrow niche contains antigen-presenting cells that may be rendered tumoricidal. Given the complexity of the bone marrow microenvironment, the mechanistic basis of such immunotherapeutic responses is not known. Through a functional characterization of antitumor CD4+ T-cell responses within the bone marrow microenvironment, we found that killing of myeloma cells is orchestrated by a population of bone marrow-resident CD11b+F4/80+MHC-IIHigh macrophages that have taken up and present secreted myeloma protein. The present results demonstrate the potential of resident macrophages as powerful mediators of tumor killing within the bone marrow and provide a basis for novel therapeutic strategies against multiple myeloma and other malignancies that affect the bone marrow.
引用
- Haabeth OAW, Hennig K, Fauskanger M, et al. CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages. Blood Adv. 2020. PMID: 32544236. doi:10.1182/bloodadvances.2020001434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。